نتایج جستجو برای: anidulafungin

تعداد نتایج: 458  

Journal: :Journal of clinical microbiology 2008
M A Pfaller D J Diekema D L Gibbs V A Newell K P Ng A Colombo J Finquelievich R Barnes J Wadula

We examined data from the ARTEMIS DISK Antifungal Surveillance Program to describe geographic and temporal trends in the isolation of Candida parapsilosis from clinical specimens and the in vitro susceptibilities of 9,371 isolates to fluconazole and voriconazole. We also report the in vitro susceptibility of bloodstream infection (BSI) isolates of C. parapsilosis to the echinocandins, anidulafu...

Journal: :Antimicrobial agents and chemotherapy 2013
Antigoni Elefanti Johan W Mouton Paul E Verweij Athanassios Tsakris Loukia Zerva Joseph Meletiadis

Antifungal combination therapy with voriconazole or amphotericin B and an echinocandin is often employed as primary or salvage therapy for management particularly of refractory aspergillosis. The pharmacodynamic interactions of amphotericin B- and voriconazole-based combinations with the three echinocandins caspofungin, micafungin, and anidulafungin in the presence of serum were tested against ...

2017
Michael A. Pfaller Shawn A. Messer Paul R. Rhomberg Mariana Castanheira

The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All Candida albicans (n = 251), Candida tropicalis (n = 51), Candida krusei (n = 16), and Candida dubliniensis (n = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible o...

2010
Melanie T. Cushion Michael J. Linke Alan Ashbaugh Tom Sesterhenn Margaret S. Collins Keeley Lynch Ronald Brubaker Peter D. Walzer

Fungi in the genus Pneumocystis cause pneumonia (PCP) in hosts with debilitated immune systems and are emerging as co-morbidity factors associated with chronic diseases such as COPD. Limited therapeutic choices and poor understanding of the life cycle are a result of the inability of these fungi to grow outside the mammalian lung. Within the alveolar lumen, Pneumocystis spp., appear to have a b...

2016
Kari-Mette Andersen Anne Karin Kristoffersen André Ingebretsen Katharina Johnsen Vikholt Ulf Thore Örtengren Ingar Olsen Morten Enersen Peter Gaustad

BACKGROUND Increasing numbers of immunocompromised patients have resulted in greater incidence of invasive fungal infections with high mortality. Candida albicans infections dominate, but during the last decade, Candida glabrata has become the second highest cause of candidemia in the United States and Northern Europe. Reliable and early diagnosis, together with appropriate choice of antifungal...

2018
Narges Aslani Ghasem Janbabaei Mahdi Abastabar Jacques F Meis Mahasti Babaeian Sadegh Khodavaisy Teun Boekhout Hamid Badali

BACKGROUND Opportunistic infections due to Candida species occur frequently in cancer patients because of their inherent immunosuppression. The aim of the present study was to investigate the epidemiology of yeast species from the oral cavity of patients during treatment for oncological and haematological malignancies. METHODS MALDI-TOF was performed to identify yeasts isolated from the oral ...

Journal: :The Journal of antimicrobial chemotherapy 2015
Meng Xiao Xin Fan Sharon C-A Chen He Wang Zi-Yong Sun Kang Liao Shu-Lan Chen Yan Yan Mei Kang Zhi-Dong Hu Yun-Zhuo Chu Tie-Shi Hu Yu-Xing Ni Gui-Ling Zou Fanrong Kong Ying-Chun Xu

OBJECTIVES To define the antifungal susceptibility patterns of the most common non-albicans Candida spp. in China. METHODS We evaluated the susceptibilities to nine antifungal drugs of Candida parapsilosis species complex, Candida tropicalis, Candida glabrata species complex and Candida krusei isolates from patients with invasive candidiasis at 11 hospitals over 3 years. Isolates were identif...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید